Glyxambi

WHAT IS GLYXAMBI?

HOW DOES GLYXAMBI WORK?

WHAT ARE THE INDICATIONS FOR GLYXAMBI?

WHAT IS THE DOSE OF GLYXAMBI?

WARNINGS AND PRECAUTIONS

Glyxambi has been reported to cause acute pancreatitis. This seems to be caused by linagliptin. Patients should be carefully monitored for this complication. If pancreatitis is diagnosed, Glyxambi should be stopped immediately.

Hypotension

Glyxambi has been reported to cause a reduction in blood volume, leading to low blood pressure. This seems to be caused by empagliflozin. This occurs more commonly in patients with renal impairment, older patients, and patients with preexisting low blood pressure.

Impaired renal function

Glyxambi causes an increase in serum creatinine. This is mediated by empagliflozin. It occurs more commonly in elderly patients and those with preexisting renal dysfunction.

Hypoglycemia

Glyxambi, when used together with insulin or drugs that stimulate the secretion of insulin, can cause low blood sugar (hypoglycemia). A lower dose of insulin or insulin secretion stimulators should be used when used in combination with Glyxambi.

Genital fungal infections

Glyxambi increases the risk of developing fungal infections on the genitals.

Urinary tract infections

Glyxambi increases the risk of developing infections in the urinary tract.

Hypersensitivity

There have been reports of severe hypersensitivity reactions in patients taking Glyxambi. These generally occur within three months of starting treatment.

SPECIAL POPULATIONS

Glyxambi has not been studied well in pregnant women. Evidence suggests that Glyxambi does not affect the fetus. Its use in pregnancy should only be considered if the benefits outweigh the potential fetal risk.

Breastfeeding

Glyxambi is excreted in breast milk. Only use Glyxambi if the benefits to the mother outweigh the possible risk to the infant.

Pediatrics

The safety of Glyxambi in pediatric patients under the age of 18 has not been established.

Elderly

When used in patients 75 years or older, there is an increased incidence of osmotic diuresis. This increases the risk of hypotension and renal failure.

Renal impairment

In patients taking Glyxambi, renal function should be checked on a regular basis. It should not be started in patients with a renal function less than 45 ml/min/1.73 m². If renal function deteriorates below with level, Glyxambi should be stopped.

Hepatic impairment

Glyxambi can be safely used in patients with hepatic impairment.

CONTRAINDICATIONS

• Severe renal impairment or renal failure
• Hypersensitivity to linagliptin or empagliflozin

SIDE EFFECTS

• Nausea
• Diarrhea
• Lack of appetite
• Fatigue
• Dizziness
• Stuffy nose
• Runny nose
• Sore throat
• Infections in the upper respiratory tract

Less common side effects include:

• Urinary tract infections
• Fungal infections on the genitals
• Hypoglycemia
  • Headache
  • Drowsiness
  • Weakness
  • Confusion
  • Irritability
  • Hunger
  • Sweating
  • Feeling jittery
• Low blood pressure
• Problems with your kidneys
• Increased levels of cholesterol in your blood
• Acute pancreatitis
• Hypersensitivity reactions
  • Swelling of your body, in particular your face or throat.
  • Difficulty swallowing
  • Difficulty breathing
  • Skin rash and raised red areas

If any of these side effects are noticed, a doctor should be consulted urgently.

DRUG INTERACTIONS

• Diuretics
• Insulin
• Insulin secretagogues
• Rifampicin